Login to Your Account



Simcere goes private for $490M, frees itself from public reporting

By Shannon Ellis
Staff Writer

Thursday, January 2, 2014

SHANGHAI – Simcere Pharmaceutical Group has completed a management buyout first announced in March and subsequent delisting from the New York Stock Exchange (NYSE:SCR). Going private will protect the company from revealing information publicly during a sensitive time as Chinese biopharmas have been rocked by bribery scandals for the past six months.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription